Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linperlisib + bortezomib + lenalidomide + dexamethasone
- Development stage
- Phase 2
- Lead developer
- Yingli Pharma
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
A quadruplet therapy combining linperlisib (a PI3K inhibitor), bortezomib (a proteasome inhibitor), lenalidomide (an immunomodulatory agent), and dexamethasone (a corticosteroid). This combination would theoretically target multiple myeloma through different mechanisms of action. The triplet of bortezomib, lenalidomide, and dexamethasone (RVd) is a well-established regimen for multiple myeloma treatment, showing high response rates and improved survival outcomes.
02
Targets
PSMB5 (Proteasome subunit beta Type-5)GR (Glucocorticoid receptor)PIK3CD (Phosphatidylinositol 3-kinase delta)CRBN (Cereblon)
Beyond the preview
Go deeper on linperlisib + bortezomib + lenalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linperlisib + bortezomib + lenalidomide + dexamethasone.